Women's College Hospital
Toronto, Ontario, M5S 1B2, Canada
NCT Number: NCT02308592
The purpose of this pilot study is to examine the feasibility of conducting a multi-site randomized controlled trial whose aim will be to evaluate the effectiveness of a Patient Decision Aid (PDA) for antidepressant use in pregnancy.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Toronto, Ontario, M5S 1B2, Canada
Depression in pregnancy is common, affecting up to 10% of women and represents serious risk to mother and infant. Unfortunately, antidepressant medication, a first-line treatment for depression in pregnancy, also comes with risks, making this a complex decision. Clinical care appears to be insufficient for ensuring that women make decisions that are consistent with their own values and with which they feel satisfied. Patient decision support tools can address such barriers. We have created a patient decision aid (PDA) that has the potential to improve the decision-making process for women regarding antidepressant use in pregnancy in conjunction with clinical care. The overall objective of this project is to inform the development of a larger, international RCT to assess the efficacy of our PDA for antidepressant use in pregnancy. To achieve this objective, we will assess the feasibility of our clinical trial protocol to evaluate the PDA and determine the preliminary effect size for a larger multi-site efficacy study. The primary outcome for this pilot study is the feasibility of conducting a large randomized controlled trial to evaluate the efficacy of the PDA. This includes feasibility (how well the trial protocol can be implemented), acceptability (usability and tolerability of the intervention) and adherence (the degree to which the trial protocol is followed). We hypothesize that our protocol will be feasible, that the PDA will have a high degree of acceptability, and that adherence to the protocol will be high.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:
Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization.
Time frame: Up to one year from when the study starts enrolling participants
Feasibility: Number of participants recruited into the study over Number of eligible patients
Time frame: Baseline (pre-randomization)
Time frame: Baseline (pre-randomization)
Time frame: Baseline (pre-randomization)
Time frame: Baseline (pre-randomization)
Time frame: 4 Weeks post-randomization
Time frame: 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), only for participants who are seeing specialty psychiatric services
Time frame: 4 Weeks post-randomization
Time frame: 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), only for participants who are seeing specialty psychiatric services
Time frame: 4 Weeks post-randomization
Time frame: 4 Weeks post-randomization
Time frame: 4 Weeks post-randomization
Time frame: After all other participant data has been collected
Time frame: Baseline (pre-randomization)
Time frame: 4 Weeks post-randomization
Time frame: 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), only for participants who are seeing specialty psychiatric services
Time frame: 4 weeks post-randomization
Time frame: 4 Weeks post-randomization
Time frame: After all participant data has been collected
Time frame: 4 Weeks post-randomization
Composite measure comprised of: (1) number of participants who complete the PDA, (2) length of time required to complete the PDA, (3) number of log ins, (4) number of times the PDA is completed per participant, (5) total number of webpages viewed).
Time frame: 4 weeks post-randomization, only for participants who are seeing specialty psychiatric services
Time frame: 4 Weeks post-randomization
Time frame: 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), OR at 4 weeks post-randomization for women who are NOT seeing specialty perinatal psychiatry services
Women's College Hospital
Other
Patient Decision Aid (PDA) for Antidepressant Use In Pregnancy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05628675
Behavior, Behavioral Symptoms
London, United Kingdom
View Trial DetailsNCT03632863
Behavior, Behavioral Symptoms
Toronto, Ontario, Canada
View Trial DetailsNCT04630249
Anxiety, Anxiety Disorders
Charleston, South Carolina, United States
View Trial DetailsNCT02519790
Anxiety Disorders, Behavior
Chicago, Illinois, United States
View Trial Details